NULISA: Ultra-Sensitive & Multiplex Immunoassay Platform for Fluid-Based Neurodegenerative Biomarker Detection
Time: 9:00 am
day: Conference Day Two
Details:
- New biomarker assay technology, NULISA™ – with ultra-sensitive femtogram level detection with proprietary background suppression technology
- Unique NULISA CNS Disease Panel detecting nearly 120 critical biomarkers covering Alzheimer’s and Parkinson's Disease as well as other CNS-related diseases
- Ultra-sensitive NULISA technology holds great promise to enable early detection and monitoring of neurodegenerative diseases to aid in new therapeutic development
